urapidil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
vasodilators 2796 34661-75-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • urapidil
  • ebrantil
  • eupressyl
  • mediatensyl
  • uraprene
  • uropidil
  • urapidil hydrochloride
  • urapidil HCl
  • Molecular weight: 387.48
  • Formula: C20H29N5O3
  • CLOGP: 2.44
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 68.36
  • ALOGS: -2.86
  • ROTB: 7

Drug dosage:

DoseUnitRoute
0.12 g O
50 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 19 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 15 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.64 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 78 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.75 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.10 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1981 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 165.24 59.73 53 292 47046 2310694
Hypotension 153.41 59.73 46 299 32390 2325350
Acute kidney injury 133.15 59.73 40 305 28082 2329658
Bradycardia 86.95 59.73 23 322 9958 2347782
Hyponatraemia 84.91 59.73 24 321 13301 2344439
Orthostatic hypotension 63.13 59.73 14 331 2865 2354875

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 117.00 52.67 39 257 27175 1719310
Acute kidney injury 81.59 52.67 32 264 34912 1711573
Coma 58.57 52.67 17 279 7245 1739240

Pharmacologic Action:

SourceCodeDescription
ATC C02CA06 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
Alpha-adrenoreceptor antagonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive emergency indication 132721000119104

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.85 Basic
pKa2 2.48 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 7.10 WOMBAT-PK KEGG DRUG
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 7.90 WOMBAT-PK KEGG DRUG
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 8.85 WOMBAT-PK KEGG DRUG
5-hydroxytryptamine receptor 1A GPCR Ki 9.46 WOMBAT-PK

External reference:

IDSource
C0077857 UMLSCUI
D01333 KEGG_DRUG
005866 NDDF
39230 RXNORM
698807007 SNOMEDCT_US
A78GF17HJS UNII
3169 INN_ID
CHEMBL279229 ChEMBL_ID
64887-14-5 SECONDARY_CAS_RN
CHEBI:32278 CHEBI
CHEMBL1256716 ChEMBL_ID
DB12661 DRUGBANK_ID
5639 PUBCHEM_CID
C015568 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None